Wheler, J. J., Atkins, J. T., Janku, F., Moulder, S. L., Stephens, P. J., Yelensky, R., . . . Meric-Bernstam, F. (2016). Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors. Oncoscience.
Citação norma ChicagoWheler, Jennifer J., et al. "Presence of Both Alterations in FGFR/FGF and PI3K/AKT/mTOR Confer Improved Outcomes for Patients With Metastatic Breast Cancer Treated With PI3K/AKT/mTOR Inhibitors." Oncoscience 2016.
Citação norma MLAWheler, Jennifer J., et al. "Presence of Both Alterations in FGFR/FGF and PI3K/AKT/mTOR Confer Improved Outcomes for Patients With Metastatic Breast Cancer Treated With PI3K/AKT/mTOR Inhibitors." Oncoscience 2016.